Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 00074-3109
Overview of NDC 00074-3109
The National Drug Code (NDC) 00074-3109 corresponds to Lovenox (enoxaparin sodium), an injectable anticoagulant used for deep vein thrombosis (DVT), pulmonary embolism (PE), and other thrombosis-related conditions. It is manufactured by Sanofi.
Current Market Landscape
Market Size & Prescription Trends
- US Market Size (2022): Estimated at approximately $2.2 billion.
- Prescription Volume (2022): About 3 million doses dispensed.
- Patient Demographics: Primarily used in post-surgical, orthopedic, and oncology settings, with increased adoption in outpatient settings due to shifting protocols.
- Competitive Landscape: Dominated by generic enoxaparin products. Originator Sanofi's brand accounts for roughly 60-70% of sales, with generics capturing the remaining share.
Regulatory & Patent Status
- Patent Expiry: Sanofi's patent on Lovenox expired in 2012; multiple generics entered the market afterward.
- Regulatory Approvals: Several biosimilars approved in the US, Europe, and other markets, increasing competition.
Market Drivers
- Increasing prevalence of conditions requiring anticoagulation, such as DVT and PE.
- Growing approval for extended prophylaxis in surgical and medical patients.
- Adoption trends favoring outpatient management, reducing inpatient costs.
Pipeline & New Entrants
- Multiple biosimilar enoxaparin products are under development or have received approval, such as Mvasi (hospital use), which impacts pricing and market share.
- Potential future entrants may include new anticoagulant classes or reformulations.
Price Analysis & Projections
Current Pricing
- Brand (Lovenox): Retail price per pre-filled syringe ranges from $150 to $250, depending on dosage.
- Generic & Biosimilars: Prices have declined by approximately 35-50% post-generic entry, with prices around $70–$160 per syringe.
Pricing Trends (2018-2022)
| Year |
Average Price per Syringe |
Notes |
| 2018 |
~$220 |
Pre-generic dominance |
| 2020 |
~$180 |
Entry of biosimilars begins to influence prices |
| 2022 |
~$125 |
Multiple biosimilars on market, further price pressure |
Projection Model Assumptions
- Continued increase in biosimilar adoption.
- Market expansion in outpatient and outpatient surgery settings.
- Stable overall demand, with slight growth driven by aging populations.
Price Projection (2023–2028)
| Year |
Estimated Average Price per Syringe |
Rationale |
| 2023 |
~$115 |
Biosimilar competition stabilizes prices |
| 2024 |
~$105 |
Increased biosimilar penetration reduces prices further |
| 2025 |
~$95 |
Market saturation of biosimilars continues, shifts to generics |
| 2026 |
~$90 |
Slight price stabilization, market maturity |
| 2027 |
~$85 |
Potential introduction of newer biosimilars or formulations |
| 2028 |
~$80 |
Pressure from generics and biosimilars persists |
Pricing Influences & Market Dynamics
- Biosimilar Penetration: As biosimilars capture a larger market share, prices decrease by an estimated 10–15% annually.
- Policy & Reimbursement: CMS and private insurers’ formulary decisions influence list prices and rebate practices.
- Global Competition: Price elasticity differs across regions; Europe sees more aggressive biosimilar adoption, impacting US market dynamics via imported products.
Risks & Opportunities
Risks
- Potential regulatory barriers delaying biosimilar approval.
- Patent suits or patent challenge outcomes affecting biosimilar entry.
- Market shifts toward alternative anticoagulants like DOACs (e.g., rivaroxaban), reducing enoxaparin use.
Opportunities
- Development of long-acting formulations.
- Expansion into emerging markets with growing cardiac and surgical procedures.
- Adoption in outpatient settings driven by healthcare cost pressures.
Key Takeaways
- The US market for NDC 00074-3109 (Lovenox/enoxaparin) currently exceeds $2 billion annually.
- Generic and biosimilar products have driven prices down by over 50% since 2018.
- Price projections suggest continued decline to around $80–$100 per syringe by 2028, aligned with biosimilar market penetration.
- Market growth will depend on adoption levels, regulatory pathways, and competition from oral anticoagulants.
FAQs
1. How has biosimilar entry affected enoxaparin pricing? Biosimilars have reduced prices by approximately 35–50%, with ongoing downward pressure expected as market share shifts.
2. What is the outlook for enoxaparin in the outpatient setting? Improved outpatient protocols and biosimilar availability are expected to increase use outside hospitals, supporting revenue growth but pressure on prices.
3. Are there upcoming patent challenges for Lovenox? While the original patent expired in 2012, legal proceedings around biosimilar patents could influence timeline and market entry.
4. How do oral anticoagulants impact enoxaparin demand? Growing use of direct oral anticoagulants (DOACs) in certain indications may reduce enoxaparin prescriptions, especially in low-risk or long-term prophylaxis.
5. What are key factors influencing future enoxaparin prices? Biosimilar adoption rates, healthcare policy changes, and competitive innovations are primary drivers.
References
[1] IQVIA IMS Health, 2022. US pharmaceutical market data.
[2] Pharmacoeconomics & Outcomes News, 2022. Market trends in anticoagulation.
[3] FDA, 2022. Biosimilar approvals and guidance.
[4] Sanofi, 2022. Lovenox product information.
[5] EvaluatePharma, 2022. Drug pricing and market forecasts.
